Sensus Healthcare (NASDAQ:SRTS - Get Free Report) is projected to release its Q1 2025 earnings data after the market closes on Thursday, May 15th. Analysts expect Sensus Healthcare to post earnings of $0.04 per share and revenue of $7.23 million for the quarter.
Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. On average, analysts expect Sensus Healthcare to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Sensus Healthcare Price Performance
SRTS traded up $0.05 during trading on Tuesday, hitting $4.12. 35,705 shares of the stock traded hands, compared to its average volume of 309,548. Sensus Healthcare has a twelve month low of $3.61 and a twelve month high of $9.33. The company has a market cap of $67.88 million, a price-to-earnings ratio of 10.29 and a beta of 1.30. The business has a 50 day moving average price of $4.62 and a 200 day moving average price of $6.25.
Wall Street Analyst Weigh In
Several research firms have recently commented on SRTS. Lake Street Capital decreased their target price on shares of Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating for the company in a research report on Tuesday, March 11th. HC Wainwright restated a "buy" rating and set a $12.00 target price on shares of Sensus Healthcare in a research report on Friday, April 4th.
Read Our Latest Analysis on SRTS
Sensus Healthcare Company Profile
(
Get Free Report)
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Further Reading
Before you consider Sensus Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sensus Healthcare wasn't on the list.
While Sensus Healthcare currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
